These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22211347)

  • 1. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use.
    Tkacz J; Severt J; Cacciola J; Ruetsch C
    Am J Addict; 2012; 21(1):55-62. PubMed ID: 22211347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
    Campbell MD; Kolodner G; Spencer RA; DuPont RL
    J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].
    Petke Z; Csorba J; Meszaros J; Vingender I; Farkas J; Demetrovics Z; Kovacs Z; Menczel Z; Pataki Z; Simor P; Havasi A; Melles K; Marvanykovi F; Racz J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):7-17. PubMed ID: 22427466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
    Hard B
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility.
    Sigmon SC; C Meyer A; Hruska B; Ochalek T; Rose G; Badger GJ; Brooklyn JR; Heil SH; Higgins ST; Moore BA; Schwartz RP
    Addict Behav; 2015 Dec; 51():136-42. PubMed ID: 26256469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.
    Peck KR; Ochalek TA; Badger GJ; Sigmon SC
    Drug Alcohol Depend; 2020 Mar; 208():107879. PubMed ID: 31991327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Opioid Withdrawal With Buprenorphine in a Community Hospital Emergency Department: An Outreach Program.
    Edwards FJ; Wicelinski R; Gallagher N; McKinzie A; White R; Domingos A
    Ann Emerg Med; 2020 Jan; 75(1):49-56. PubMed ID: 31732373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of anxiety sensitivity on opioid use disorder treatment outcomes.
    Baxley C; Weinstock J; Lustman PJ; Garner AA
    Exp Clin Psychopharmacol; 2019 Feb; 27(1):64-77. PubMed ID: 30080059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine compliance.
    Demaria PA; Risler RB
    Am J Addict; 2012; 21(5):491. PubMed ID: 22882401
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of telephonic patient support on treatment for opioid dependence: outcomes at one year follow-up.
    Ruetsch C; Tkacz J; McPherson TL; Cacciola J
    Addict Behav; 2012 May; 37(5):686-9. PubMed ID: 22348921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 20. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.